RE:RE:RE:Ya good read from the website ...Gobbs, you may be right that the company is finding it difficult to find a partner or marketing collaboration and a change of story is needed.
What I hope for is that a different type of partnership has presented itself - one that will capitalise better on the previous work done by the company in identifying both new acute and also wound healing applications for Ryplazim.
Perhaps a private equity firm like Bain could be interested in taking a 50% share of the Ryplazim platform only for a good chunk of change upfront and on condition that it pay for all future clinical trials related to Ryplazim both acute and subcutaneous applications with a view to selling the Ryplazim platform once it has matured in a few years time.
Let’s see what happens. But I am also preparing for a worst case scenario as the cash crunch is now or will soon be hitting the company.